Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Feb 29, 2024 10:48am
153 Views
Post# 35906439

The presention will be in about one hour

The presention will be in about one hourThe deep south presentaion, as I siad legally can not release any new information without a formal N.R. first.
Saying that, the site promotional materal eludes to "over 400  oncology leaders and investment advisors"
It is very hard for us long time ONC(Y) followers to even think of the perspective that Oncolytics Biotech is very little known.
Yes. Those involved in the trials, the contacts at Roche, Pfizer, Incyte, BMS etc etc , who have dealt with ONC overr the many years, certianly are awre ONC exisist.
The 6 anlysts covering ONC are aware. 
Yet move the lens out a few feet & ONC(Y) is but a speck within the investment comunity.
More or less the same within the very large cancer therapy world.
notice it says "over 400" .
getting the message out to the right people at the right time. As opposed to the hard core, bashers we hear from again & again...is a good opportunity.
Part of "something" ? No idea.
The presentation  will come & go. 
My issue? We still are not informed of Q4/year end YET.
I find that unussual.
The reports etc, take a lot of time & planning to generate. Nothing since the cancelation of Precision promise has made sense.


<< Previous
Bullboard Posts
Next >>